Page last updated: 2024-08-21

quinazolines and Ventricular Dysfunction, Left

quinazolines has been researched along with Ventricular Dysfunction, Left in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Achenbach, H; Egyed, M; Gercheva, L; Gotic, M; Kvasnicka, HM; Warzocha, K; Wu, J1
Chang, MJ; Choi, HD1
Byrne, J; Ewer, MS; Koehler, M; Perez, EA; Preston, AJ; Rappold, E1
Greufe, S; Hayward, R; Hydock, DS; Schneider, CM; Wonders, KY1
Fowler, MB; Telli, ML; Witteles, RM1
Criscitiello, C; de Azambuja, E; de Castro, G; Diaz, M; La Gerche, A; Metzger-Filho, O; Piccart-Gebhart, MJ; Saini, KS1
Eijsman, L; van Wezel, HB; van Zwieten, PA; Visser, CA; Vroom, MB1

Reviews

3 review(s) available for quinazolines and Ventricular Dysfunction, Left

ArticleYear
Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.
    Breast cancer research and treatment, 2017, Volume: 166, Issue:3

    Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; ErbB Receptors; Female; Heart; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left

2017
Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
    Heart failure clinics, 2011, Volume: 7, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Cardiac Imaging Techniques; Cardiotoxins; Clinical Trials as Topic; Drug Monitoring; Humans; Lapatinib; Neoplasms; Outcome and Process Assessment, Health Care; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index; Trastuzumab; Ventricular Dysfunction, Left

2011
Targeted therapies in breast cancer: are heart and vessels also being targeted?
    Breast cancer research : BCR, 2012, Jun-19, Volume: 14, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Female; Heart Failure; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Trastuzumab; Ventricular Dysfunction, Left

2012

Trials

2 trial(s) available for quinazolines and Ventricular Dysfunction, Left

ArticleYear
Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
    Cardiovascular toxicology, 2021, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Aged; Biopsy; Blood Platelets; Bone Marrow Examination; Echocardiography; Europe; Female; Humans; Hydroxyurea; Male; Middle Aged; Platelet Count; Quinazolines; Stroke Volume; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left; Young Adult

2021
Hemodynamic effects of the novel selective cAMP-phosphodiesterase III inhibitor R 80122 in anesthetized patients with moderate left ventricular dysfunction before coronary artery bypass grafting.
    Journal of cardiothoracic and vascular anesthesia, 1995, Volume: 9, Issue:3

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Aged; Anesthesia, General; beta-Cyclodextrins; Blood Pressure; Cardiac Output; Cardiotonic Agents; Coronary Artery Bypass; Cyclodextrins; Echocardiography, Transesophageal; Female; Half-Life; Heart Rate; Hemodynamics; Humans; Imidazoles; Infusions, Intravenous; Male; Phosphodiesterase Inhibitors; Premedication; Prospective Studies; Pulmonary Wedge Pressure; Quinazolines; Safety; Solvents; Ventricular Dysfunction, Left

1995

Other Studies

2 other study(ies) available for quinazolines and Ventricular Dysfunction, Left

ArticleYear
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Female; Heart Failure; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Stroke Volume; Ventricular Dysfunction, Left

2008
Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Body Weight; Caspase 3; Caspase 8; Doxorubicin; Exercise Therapy; Female; Heart; Heart Ventricles; Lipid Peroxidation; Malondialdehyde; Oxidative Stress; Quinazolines; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left; Ventricular Pressure

2009